Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 10—October 2020

Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland

Andreas F. Widmer, Reno Frei, Ed J. Kuijper, Mark H. Wilcox, Ruth Schindler, Violeta Spaniol, Daniel Goldenberger, Adrian Egli, Sarah Tschudin-SutterComments to Author , and Kuijper
Author affiliations: University Hospital Basel, Basel, Switzerland (A.F. Widmer, R. Frei, R. Schindler, V. Spaniol, D. Goldenberger, A. Egli, S. Tschudin-Sutter); Leiden University Medical Center, Leiden, the Netherlands (E.J. Kuijper); Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, and Leeds Teaching Hospitals, Leeds, UK (M.H. Wilcox)

Main Article

Table 2

Underdiagnosis and misdiagnosis of Clostridioides difficile infection at participating hospitals, Switzerland*

Method of detection No. samples submitted No. samples tested Undiagnosed, no. (% of all positive samples) False-positive, no. (%) False-negative, no. (%)
EIA for GDH and A and B toxins 242 165 2 (9.5) 9 (5.5) 1 (0.6)
PCR 242 165 3 (10) 3 (1.8) 3 (1.8)

*EIA, enzyme immunoassay; GDH, glutamate dehydrogenase.

Main Article

Page created: July 24, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.